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Abstract
B cells provide humoral protection against pathogens and promote cellular immunity through 
diverse nonclassical effector functions. To assess B cell function in promoting T cell homeostasis, 
mature B cells were either acutely or chronically depleted in mice using CD20 mAb. Acute B cell 
depletion in either 2- or 4-mo-old mice significantly reduced spleen and lymph node CD4+ and 
CD8+ T cell numbers, including naive, activated, and Foxp3+CD25+CD4+ regulatory T cell 
subsets. The numbers of IFN-γ– and TNF-α–producing T cells were also significantly reduced. 
Chronic B cell depletion for 6 mo in aged naive mice resulted in a 40–70% reduction in activated 
CD4+ and CD8+ T cell numbers and 20–50% reductions in IFN-γ–producing T cells. Therefore, B 
cells were necessary for maintaining naive CD4+ and CD8+ T cell homeostasis for subsequent 
optimal T cell expansion in young and old mice. To determine the significance of this finding, a 
week of B cell depletion in 4-mo-old mice was followed by acute viral infection with lymphocytic 
choriomeningitis virus Armstrong. Despite their expansion, activated and cytokine-producing 
CD4+ and CD8+ T cell numbers were still significantly reduced 1 wk later. Moreover, viral 
peptide-specific CD4+ and CD8+ T cell numbers and effector cell development were significantly 
reduced in mice lacking B cells, whereas lymphocytic choriomeningitis virus titers were 
dramatically increased. Thus, T cell function is maintained in B cell–depleted mice, but B cells are 
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required for optimal CD4+ and CD8+ T cell homeostasis, activation, and effector development in 
vivo, particularly during responses to acute viral infection.
Blymphocytes are classically defined as the effector cells of humoral immunity that 
terminally differentiate into Ab-secreting plasma cells. However, B cells also contribute 
nonclassical functions during immunity, such as organizing lymphoid tissue organogenesis, 
positively and negatively regulating cellular immune responses, and modulating innate cell 
function (1). The nonclassical functions of B cells during cellular immune responses have 
received recent attention due to the clinical demonstration that therapeutic B cell depletion 
results in disease remission in multiple subsets of autoimmune patients (2). Even though 
patients undergoing B cell depletion therapies frequently remain B cell insufficient for 8–18 
mo, their autoantibody titers may not decrease after treatment (2). Thus, B cells must 
contribute to auto-immune pathogenesis via mechanisms in addition to autoantibody 
production. However, the cellular effects of acute or chronic B cell depletion on the human 
or mouse immune systems remain inadequately characterized, particularly during cellular 
immune responses.
The effect of short-term and chronic B cell depletion on T cell homeostasis and immune 
responses to lymphocytic choriomeningitis virus (LCMV) infection was assessed in the 
current study using naive mice with intact immune systems and a potent mAb specific for 
mouse CD20 (3, 4). CD20 is a B cell–specific surface molecule that is first expressed during 
the late pre–B cell developmental stage and downregulated early during plasma cell 
differentiation. Thus, long-lived plasma cells are not depleted by CD20 mAb, and serum Ig 
levels remain stable after CD20 mAb-induced B cell depletion (5). CD20 mAb selectively 
depletes B cells in vivo by monocyte-mediated Ab-dependent cellular cytotoxicity/
phagocytosis (3, 6, 7). More than 98% of mature B cells in the blood and primary lymphoid 
organs are depleted acutely following a single dose of CD20 mAb (MB20-11; 250 μg/
mouse), with the effect lasting 6–8 wk (8). Under these experimental conditions, B cells 
were required for spleen and lymph node CD4+ and CD8+ T cell and Foxp3+CD25+CD4+ 
regulatory T cell (Treg) homeostasis in naive mice and for optimal T cell activation and 
numerical expansion following acute LCMV infection.
Materials and Methods
Mice, Abs, and immunotherapy
C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) were housed in a specific 
pathogen-free facility. P14 mice with the LCMV gp33-H-2Db–specific TCR [B6.Cg-
Tcratm1Mom Tg(TcrLCMV)327Sdz] (9) were from Taconic Farms (Hudson, NY). All 
studies were approved by the Animal Care and Use Committees of Duke University Medical 
Center, Emory University, and the Atlanta VA Medical Center and performed in accordance 
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. Prior to B cell depletion, mice used in LCMV studies were 
housed in isolator cages in a conventional animal facility.
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To induce in vivo B cell depletion, sterile and endotoxin-free CD20 mAb (MB20-11, IgG2c; 
250 μg) or isotype-matched control mAb were injected in 200 μl PBS as described (3). Mice 
aged 2 or 4 mo were injected once with control or CD20 mAb 14 d before analysis. For 
chronic B cell–depletion studies, mice were depleted of B cells by repeated injections with 
control or CD20 mAb once a month starting at 6 mo of age for 6 mo and analyzed 14 d 
following the final injection. For migration studies, 107 B cell–depleted splenocytes labeled 
with CellTracker Orange CMRA (Invitrogen Life Technologies, Carlsbad, CA) was injected 
through the lateral tail veins of mice that had received either control or CD20 mAb 7 d prior. 
Mice were then analyzed 2 d following cell transfer.
LCMV infection
Mice were infected i.p. with 2 × 105 PFU LCMV Armstrong 53b prepared as described (10). 
Mice were infected with LCMV 7 d after treatment with control or CD20 mAb and then 
analyzed 7 d postinfection. For LCMV-specific CD8+ T cell studies, P14 CD8+ T cells (1 × 
105) were transferred through lateral tail veins 6 d after treatment with control or CD20 
mAb. Mice were then infected with LCMV 1 d later and evaluated 7 d postinfection.
Cell preparation and immunofluorescence analysis
Single-cell leukocyte suspensions from spleens and peripheral lymph nodes (axillary, 
brachial, and inguinal) were generated by gentle dissection, and erythrocytes were 
hypotonically lysed. For multicolor immunofluorescence analysis, viable single-cell 
suspensions (1 × 106) were stained on ice using predetermined optimal concentrations of 
mAb in FACS buffer (2% FCS in PBS) for 30 min or with MHC class II tetramers for 2 h at 
37°C. Cells were washed in PBS between all staining steps, and after the final wash, the 
cells were resuspended in PBS containing 1.5% paraformaldehyde and kept in the dark at 
4°C until analysis. Dead cells were excluded from data analysis by staining with LIVE/
DEAD Fixable Dead Cell Stain Kit (Invitrogen Life Technologies). Cells with the forward 
and side light scatter properties of lymphocytes were analyzed using an FACSCanto II flow 
cytometer (BD Biosciences, San Jose, CA). Background staining was assessed using 
nonreactive, isotype-matched control mAbs (Caltag Laboratories, San Francisco, CA).
Treg visualization was carried out using the Foxp3/Transcription Factor Staining Buffer Set 
(eBioscience, San Diego, CA) according to the manufacturer’s instructions. Intracellular 
cytokine staining was performed using the Cytofix/Cytoperm kit (BD Biosciences) 
according to the manufacturer’s instructions. Following the administration of control or 
CD20 mAb 14 d prior, spleen lymphocytes were isolated and depleted of B cells using 
CD19 mAb-coated magnetic beads (Invitrogen Life Technologies). The remaining non–B 
cells were cultured in vitro with plate-bound CD3ε (1 μg/ml) and CD28 (10 μg/ml) mAbs 
for 3.5 h in the presence of the secretion inhibitor brefeldin A (5 μg/ml; BD Biosciences) to 
identify T cells that were actively producing cytokines in vivo. The cells were stained for 
surface CD4 and CD8 and cytoplasmic IFN-γ and TNF-α expression and analyzed by flow 
cytometry. To quantify LCMV-specific T cell responses, T cells were stimulated with 
GP33–41 (CD8+ T cells) and GP61–80 (CD4+ T cells) peptides (10 μg/ml; AnaSpec, Fremont, 
CA) in the presence of brefeldin A for 5 h before cell-surface and intracellular cytokine 
staining.
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FITC-, PE-, PE-Cy5-, allophycocyanin, or PE-Cy7–conjugated Abs for staining were as 
follows: CD4 (H129.19), CD8 (53-6.7), CD44 (IM7), IFN-γ (XMG1.2), Ly6C (AL-21), 
PSGL1 (2PH1), and TNF-α (MP6-XT22) mAbs were from BD Biosciences; B220 
(RA36B2), CD25 (PC61), CD127 (A7R34), and killer cell lectin-like receptor G1 (KLRG1)/
MAFA (2F1) were from BioLegend (San Diego, CA); L-selectin (CD62L; clone 
LAM1-116) mAb was as described (11); and Foxp3 (FJK-16s) mAb and functional-grade 
CD3ε (145-2C11) and CD28 (37.51) mAbs were from eBioscience. The MHC class I 
tetramers, DbGP33–41 (GP33), used to identify LCMV-specific CD8+ T cells were generated 
as described (12). The MHC class II tetramer I-AbGP66–77 (GP66; National Institutes of 
Health Tetramer Facility) was used to identify LCMV-specific CD4+ T cells.
Viral RNA quantification
RNA extracted from purified spleen lymphocytes was used to generate cDNA, with relative 
transcript levels determined by real-time quantitative RT-PCR of triplicate samples as 
described (13). Transcripts were amplified using gapdh- and LCMV glycoprotein-specific 
primers as described (13, 14). Cycle conditions were as follows: 1 denaturation step of 95°C 
for 2 min followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 1 min. The 
specificity of RT-PCR products was confirmed by melting curve analysis. Viral RNA 
expression threshold values (2−ΔΔCt) were determined by normalizing viral RNA transcript 
levels to gapdh expression within both sample groups and then to one sample from a mouse 
treated with control mAb.
Statistical analysis
All data are shown as individual data points or as means ± SEM. The significance of 
differences between sample means was determined using the unpaired Student t test, with 
Welch’s correction for unequal variances where appropriate.
Results
Acute B cell depletion by CD20 mAb reduces CD4+ and CD8+ T cell numbers
Studies examining the effects of CD20 mAb-induced B cell depletion on T cell numbers and 
function have generated variable findings (3, 15–20). Therefore, the effect of short-term B 
cell depletion on spleen and lymph node T cell frequencies and numbers was compared in 
littermate groups of 2- and 4-mo-old fully mature mice in which B and T cell numbers are 
stable. Tissue lymphocyte subsets were analyzed 14 d after a single dose of control or CD20 
mAb treatment to optimally evaluate the effect of B cell depletion on T cell homeostasis. In 
all mice, spleen and lymph node B220+ B cell numbers were reduced by >99% in littermates 
given the MB20-11 CD20 mAb relative to control mAb (Fig. 1A). Consequently, the 
frequencies of CD4+ and CD8+ T cells among lymphocytes were increased. However, total 
spleen and lymph node CD4+ and CD8+ T cell numbers in 2-mo-old B cell–depleted mice 
were overlapping with control mAb-treated mice, but mean values were decreased by 44–
53% (Fig. 1B, 1C), although variability was observed between individual mice and groups 
of littermate mice in four independent experiments. Mean CD4+ and CD8+ T cell numbers 
in 4-mo-old mice given CD20 mAb were similarly reduced by 35–40% and 54–62% in the 
spleen and lymph nodes, respectively, with a range of variability between mice and 
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littermate groups between different experiments. Treg frequencies within spleens and lymph 
nodes did not change following B cell depletion, although total Treg cell numbers were 
significantly reduced (2 mo old, 55–57%; 4 mo old, 47–61%; Fig. 1D). The migration of 
adoptively transferred CD4+ and CD8+ T cells into blood, the spleen, and lymph nodes was 
not significantly affected by the absence of B cells, as transferred dye-labeled cells migrated 
normally into tissues (p > 0.05, Fig. 1E, 1F). However, when endogenous T cell numbers 
were reduced in CD20 mAb-treated mice, transferred T cell numbers were reduced 
similarly. Thus, B cell depletion significantly reduced overall CD4+ and CD8+ T cell and 
Treg homeostasis in 2- and 4-mo-old naive mice relative to control mAb-treated littermates.
Acute B cell depletion reduces both naive and activated T cell numbers
The effect of B cell depletion on spleen T cell subsets with naive CD44loCD62Lhi and 
activated CD44hiCD62Llo phenotypes was quantified relative to all CD4+ or CD8+ 
lymphocytes. The frequencies of activated CD4+ and CD8+ T cells were reduced by 30–
38% in 2-mo-old mice treated with CD20 mAb in comparison with control mAb-treated 
littermates (Fig. 2A, 2B). The numbers of activated CD4+ and CD8+ T cells were reduced 
by 52–68% and 47–66% in 2- and 4-mo-old mice, respectively. B cell depletion reduced 
total naive CD4+ and CD8+ T cell numbers by 40–50% in 2-mo-old mice and by 35–37% in 
4-mo-old mice. Thus, mean numbers of naive and activated CD4+ and CD8+ T cells were 
decreased in CD20 mAb-treated mice relative to littermate controls.
As cytokine production is an integral component of the effector T cell immune response, the 
effects of B cell depletion on T cell cytokine production were quantified. IFN-γ– and TNF-
α–expressing CD4+ and CD8+ T cell frequencies were not profoundly altered in either 2- or 
4-mo-old mice after CD20 mAb treatment for 14 d (Fig. 2C, 2D). However, mean IFN-γ– 
and TNF-α–expressing CD4+ T cell numbers were reduced by 58–61% and 51–54%, 
respectively, in B cell–depleted 2- and 4-mo-old mice, whereas mean IFN-γ– and TNF-α–
expressing CD8+ T cell numbers were reduced by 51–59% and 36–49%, respectively. Thus, 
B cell depletion significantly reduced the total numbers of cytokine-producing CD4+ and 
CD8+ T cells relative to control mAb-treated littermates.
Chronic B cell depletion reduces activated CD4+ T cell numbers
Whether the effects of B cell depletion on T cell homeostasis observed in young mice were 
age-associated was assessed using naive 6-mo-old mice with fully mature immune systems 
that were then treated monthly with CD20 mAb for 6 mo. Spleen and lymph node B220+ B 
cell numbers were decreased by >98% after chronic B cell depletion (Fig. 3A). Spleen CD4+ 
T cell numbers were decreased by 51% in CD20 mAb-treated mice, including a 56% 
decrease in Treg cell numbers. Mean lymph node CD4+ T cell and Treg cell numbers were 
reduced by 48 and 63%, respectively. Spleen and lymph node CD8+ T cell numbers were 
affected less by chronic B cell depletion.
Chronic B cell depletion significantly reduced activated CD44hi CD62Llo CD4+ and CD8+ T 
cell frequencies by 40 and 48%, respectively (Fig. 3B). Activated CD4+ and CD8+ T cell 
numbers were also decreased by 70 and 44%, respectively, whereas total CD8+ and naive 
CD44loCD62Lhi CD4+ T cell numbers did not change significantly with chronic B cell 
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depletion. Consistent with these changes, mean IFN-γ–producing CD4+ T cell frequencies 
were decreased by 50% in B cell–depleted mice, but mean TNF-α–producing CD4+ T cell 
and IFN-γ– and TNF-α–producing CD8+ T cell frequencies were not changed significantly 
(Fig. 3C, 3D). Additionally, the numbers of IFN-γ– and TNF-α–producing CD4+ T cells 
were reduced by 70 and 40%, respectively, following B cell depletion, whereas the numbers 
of IFN-γ+ and TNF-α+ CD8+ T cells were unaffected. Thus, as occurred with acute B cell 
depletion, chronic B cell depletion in older mice significantly reduced the proportion and 
number of activated CD4+ and CD8+ T cells and only reduced cytokine-producing CD4+ T 
cell numbers relative to their control mAb-treated littermates.
B cell depletion impairs virus clearance in LCMV-infected mice
To understand whether reduced CD4+ and CD8+ T cell homeostasis in B cell–depleted mice 
affected cellular immune responses, 4-mo-old mice were given CD20 or control mAb 7 d 
before infection with LCMV Armstrong. Spleen CD4+ and CD8+ T cell numbers were 
assessed 7 d postinfection. In control mAb-treated mice, LCMV infection reduced mean 
CD4+ T cell numbers by 33% relative to uninfected mice (Fig. 4A). Prior CD20 mAb 
treatment significantly reduced CD4+ T cell numbers in virus-infected mice relative to 
infected control mAb-treated mice (23%). Treg numbers were comparably reduced during 
LCMV infection in B cell–depleted mice (30%, Fig. 4B). In contrast to CD4+ T cells, 
LCMV infection induced an ~3-fold expansion in CD8+ T cell numbers following control 
mAb treatment relative to naive mice. However, virus-induced CD8+ T cell expansion was 
profoundly inhibited following B cell depletion (42%, Fig. 4A). Thus, B cell depletion 
reduced total CD8+ T cell numbers generated in response to acute virus infection.
The effect of reduced T cell numbers in B cell–depleted mice on in vivo viral clearance was 
assessed by quantifying relative LCMV RNA levels as described (14). Spleen viral RNA 
levels were 48-fold higher in B cell–depleted mice relative to control mAb-treated mice 7 d 
postinfection (Fig. 4C). Accordingly, the numbers of activated CD44hiCD62L− CD4+ T 
cells were reduced by 54–60% in the spleen and lymph nodes, whereas naive CD4+ T cell 
numbers were less affected by B cell depletion following viral infection (Fig. 4D). Similarly, 
CD4+ effector (Ly6C+PSGL1+), prememory (Ly6C− PSGL1+), and T follicular helper 
(Ly6C− PSGL1−) cell numbers were reduced by 69–84% in the spleen, with comparable 
reductions in the numbers of prememory (62%) and T follicular helper (68%) CD4+ T cells 
within the lymph nodes of B cell–depleted mice infected with LCMV (Fig. 4E) (21). 
Although naive CD8+ T cell numbers were normal following virus infection in B cell–
depleted mice, the numbers of activated CD44hiCD62L− spleen and lymph node CD8+ T 
cells were reduced by 51–52%, (Fig. 4F). CD8+ KLRG1+ effector T cell numbers were also 
reduced by 64–74% in the spleen and lymph nodes of B cell–depleted mice that were 
infected with LCMV (Fig. 4G) (21). Thus, B cells were needed for the optimal generation of 
CD4+ and CD8+ T cells with an activated phenotype and the expansion of effector cell 
subsets following infection.
B cell depletion significantly reduced the frequencies (47–50%) and numbers (51–53%) of 
spleen IFN-γ– and TNF-α–expressing CD4+ T cells in infected mice (Fig. 5A). Although the 
relative frequencies of IFN-γ– and TNF-α–expressing CD8+ T cells were not altered in B 
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cell–depleted and infected mice, IFN-γ– and TNF-α–expressing CD8+ T cell numbers were 
reduced by 35 and 44%, respectively (Fig. 5B). Thus, B cell depletion impaired CD4+ T cell 
cytokine production during immune responses to LCMV, but did not reduce the relative 
frequencies of CD8+ T cells producing cytokines despite their overall reduced numbers in B 
cell–depleted mice.
B cell depletion impairs Ag-specific T cell responses
Consistent with reduced T cell numbers in B cell–depleted mice after LCMV infection, 
CD20 mAb treatment reduced mean spleen LCMV peptide-specific CD4+ (GP66+) and 
CD8+ (GP33+) T cell numbers by 67% (Fig. 6A). B cell depletion significantly reduced the 
numbers of activated GP66-specific CD44hiCD62L− CD4+ T cells (87–91%) and the 
numbers of effector (58–71%), pre-memory (90–94%), and T follicular helper (84–91%) 
subsets in the spleen and lymph nodes following LCMV infection (Fig. 6B). Virus-specific 
CD4+ and CD8+ T cell cytokine production was therefore assessed using B cell–depleted 
splenocytes from LCMV-infected mice that were restimulated with LCMV peptides in vitro 
for 5 h. B cell depletion reduced both virus-specific IFN-γ+ and TNF-α+ CD4+ T cell 
frequencies (56–62%) and numbers (72–75%) in infected mice (Fig. 6C). By contrast, the 
frequencies of GP33-specific CD8+ T cells expressing IFN-γ+ and TNF-α+ were not 
changed, but mean numbers of GP33-specific CD8+ T cells expressing IFN-γ+ and TNF-α+ 
were reduced (52–63%) in B cell–depleted LCMV-infected mice (Fig. 6D). Thus, B cell 
depletion reduced the numbers of Ag-specific CD4+ and CD8+ T cells responding to viral 
infection.
Impaired LCMV clearance following B cell depletion may occur as a direct consequence of 
reduced T cell numbers or may result from reduced CD8+ T cell function. To address this, 
naive TCR-transgenic CD8+ T cells that recognize the dominant LCMV epitope GP33–41 
(22) were adoptively transferred into control or B cell–depleted mice prior to infection. B 
cells were not required for Ag-driven CD8+ T cell expansion, activation, or cytokine 
production in the spleen (Fig. 6E). However, effector KLRG1+ CD8+ T cell generation was 
reduced by 50% in the absence of B cells. In lymph nodes, B cell depletion significantly 
inhibited GP33+ CD8+ T cell expansion (63%), activation (67%), and KLRG1+ effector cell 
development (68%). Thus, B cell depletion impaired the induction of Ag-specific CD4+ and 
CD8+ T cells following viral infection predominantly by reducing total Ag-specific T cell 
num bers, although KLRG1+ effector cell generation was impaired.
Discussion
These collective studies demonstrate that B cells are required for spleen and lymph node T 
cell homeostasis and optimal CD4+ and CD8+ T cell responses during acute LCMV 
infection. Remarkably, short-term mature B cell depletion in both 2- and 4-mo-old mice 
significantly reduced both spleen and lymph node CD4+, CD8+, and Treg numbers (Fig. 
1B–D). These reductions were most likely due to alterations in T cell homeostasis following 
B cell depletion, as no overt changes in T cell migration to peripheral organs were observed 
(Fig. 1E, 1F). In the absence of B cells, activated CD44hiCD62L− CD4+ and CD8+ T cell 
numbers in 2- and 4 mo-old mice were more dramatically reduced than naive 
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CD44loCD62L+ CD4+ and CD8+ T cell numbers (Fig. 2A, 2B). As a consequence of fewer 
T cells in B cell–depleted mice, the number of effector CD4+ and CD8+ T cells producing 
IFN-γ and TNF-α was also significantly decreased (Fig. 2C, 2D). Importantly, B cell 
deficiency during acute LCMV infection led to significant reductions in CD4+ and CD8+ T 
cell numbers and the generation of activated, effector, and CD4+ cytokine-producing cells 
(Figs. 4, 5). Virus peptide-specific CD4+ and CD8+ T cell numbers and effector generation 
as well as CD4+ T cell activation and cytokine production were also dramatically reduced in 
mice lacking B cells (Fig. 6), whereas spleen LCMV titers were dramatically increased (Fig. 
4C). Thus, B cells were essential for maintaining CD4+ and CD8+ T cell homeostasis and 
optimal T cell responses during viral infection.
B cell depletion in 2- and 4-mo-old mice had an overall negative effect on both CD4+ and 
CD8+ T cell homeostasis and function after only 2 wk (Figs. 1, 2). Chronic B cell depletion 
over 6 mo in year-old mice similarly resulted in a 50–70% reduction in activated CD4+ and 
cytokine-producing T cell numbers, but alterations in CD8+ T cell activation were less 
dramatic (Fig. 3). In complementary studies, acute B cell depletion in mice with otherwise 
intact immune systems impairs adaptive and autoreactive CD4+ T cell responses to Ag 
challenge, whereas CD8+ T cell reactivity is less affected (16, 23). B cell depletion also 
reduces the conversion of naive CD44loCD62L+ CD4+ T cells to an activated phenotype in 
response to Listeria challenge, whereas CD8+ T cell phenotypes are only modestly affected 
(16). A role for B cells in CD4+ T cell priming has also been demonstrated in mice given 
anti-IgM Ab since birth (24–27) and in genetically B cell–deficient (μMT) mice (28). 
Therapeutic B cell depletion in mice also reduces CD4+ and CD8+ T cell tumor immunity in 
the B16 melanoma model (20). Thereby, depending on mouse age, status of the immune 
system and magnitude of the challenge, CD4+ T cell function appears to be more B cell 
dependent than CD8+ T cell function.
Acute B cell depletion in mice before LCMV infection resulted in dramatically increased 
virus titers (Fig. 4C), which is in accordance with previous studies that demonstrated 
worsened but not protracted LCMV Armstrong infection in μMT mice (29, 30). Similarly, 
mice depleted of B cells since birth with anti-IgM serum do not develop fully protective T 
cell immunity to virus-induced tumors (31, 32). B cells promote optimal T cell activation 
and function following immunization (16, 33), during viral immunity (34–37) and in models 
of tumor immunity, autoimmunity, and graft rejection (19, 20, 32, 38–41). The influence of 
B cells on both CD4+ and CD8+ T cell activation thus reflects the diverse and multiple 
known molecular mechanisms through which B cells influence T cell immunity, including B 
cell contributions to Ag presentation, costimulatory molecule expression, and cytokine 
production (1). When the immune system develops in the complete absence of B cells in 
μMT mice, multiple immune system abnormalities have been identified. The absence of B 
cells has been shown to impair CD4+ T cell priming in some studies (25, 26, 33, 42–44), 
whereas others have reported that CD4+ T cell priming is not affected in μMT mice (45–49). 
Additionally, thymocyte and T cell numbers and repertoire are decreased significantly in 
μMT mice (30, 50). Also, because B cells help to organize lymphoid organ architecture, the 
spleens of μMT mice are smaller in size (30), exhibit significant defects within the spleen 
dendritic cells (DC) and T cell compartments (46, 51), lack follicular DC and marginal zone 
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and metallophilic macrophages (52), have decreased chemokine expression (51, 52), and are 
deficient in Peyer’s patch organogenesis and follicular DC networks (52, 53). DC in μMT 
mice also skew immunity toward Th1 responses (46). B cell depletion after the 
establishment and functional maturation of lymphoid tissues as in the current studies may 
also affect nonlymphoid immune cell populations that influence LCMV clearance. 
Nonetheless, acute and chronic B cell depletion in the current studies appears to have 
primarily dampened T cell homeostasis and some cell-mediated immune responses in 
comparison with the more pleiotropic effects of con genital B cell deficiency or induced B 
cell depletion after birth.
There was a specific reduction in Ag-specific effector CD8+ cell development in the absence 
of B cells (Fig. 6E). Because CD4+ T cells are critical for CD8+ T cell responses to viral 
infection (54), the observed impact of B cell depletion on CD8+ T cell function may be due 
to B cell–induced alterations in CD4+ T cell expansion, function, and memory maintenance, 
as shown in this study and elsewhere (16, 23, 37). The absence of B cells may thereby also 
indirectly impact CD8+ T cell memory development, as memory CD8+ T cells derive from 
the responding Ag-specific effector CD8+ T cell pool (21), and there is a reduction in 
memory CD8+ T cell numbers following LCMV infection in the absence of B cells (30). 
The altered architecture of lymphoid tissues in B cell–depleted mice may also affect T cell 
responses. In either event, the delayed resolution of viral infection observed in this study 
may primarily result from reduced T cell homeostasis, resulting in lower numbers of 
activated and cytokine-producing CD4+ and CD8+ T cells responding to LCMV. Indeed, T 
cells derived from μMT mice are unable to develop memory responses sufficient to control 
persistent viral infection (29), and this effect is independent of B cell Ab production (44, 
55). B cells are also required for optimal CD4+ T cell memory generation and recall 
responses upon secondary infection, a process dependent on B cell MHC class II expression 
(23, 37). Total and Ag-specific effector, prememory, and T follicular helper CD4+ T cell 
development was also significantly inhibited in the current study. Thus, both primary and 
secondary responses to infection are likely to be significantly affected by B cell depletion.
The importance of CD20 mAb-induced B cell depletion on CD4+, Treg, and CD8+ T cell 
frequencies or numbers in mice have yielded conflicting results, ranging from increased (18, 
19) or unchanged (3, 15–17) to decreased (20, 23, 37). Variability between individual mice 
was also observed in the current studies, in which the numbers of Treg, CD4+, and CD8+ T 
cells remaining after CD20 or control mAb treatment overlap (Fig. 1B–D). In previous 
studies, differences between lymphocyte subsets among littermates, measurement of 
differences in T cell frequencies versus tissue numbers, variability between ages of mice 
being studied, differences in disease responses to treatments, inherent variability in lymph 
node sizes between littermates, and small sample groups are likely to have obscured 
differences between CD20 or control mAb-treated groups. The degree of B cell depletion 
due to the use of different CD20 mAbs and treatment regimens is also important, as changes 
in cell numbers and lymphoid tissue architecture are less pronounced when some B cells 
remain. For example, B cell depletion by CD20 mAb is less effective in NOD mice, due in 
part to FcγR deficiencies (41). CD20 mAb treatment significantly reduces the proliferative 
capacity of CD4+ and CD8+ T cells within tissues of NOD mice, but does not affect Treg, 
CD4+, or CD8+ T cell numbers or phenotypes. Others have also demonstrated impaired 
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lymph node T cell activation in congenitally μMT NOD mice, suggesting a critical need for 
B cell costimulatory signals (56). The timing of evaluation following B cell depletion is also 
critical (3, 4), as the reductions in total CD4+ and CD8+ T cell numbers 1 wk following 
CD20 mAb treatment are less significant than those that were observed 2 wk after depletion 
(Fig. 1) (16). The global effects on T cell homeostasis induced by B cell depletion likely 
change with disease severity and also with age, as was observed for mice chronically 
depleted of B cells in this study. Nonetheless, reduced numbers of activated and effector 
cytokine-producing CD4+ T cells are most likely attributable to suboptimal activation in the 
absence of B cell Ag presentation in combination with normal T cell turnover (16, 20, 37, 
39, 57).
B cell depletion reduces the pathogenesis of diverse autoimmune diseases in humans, in 
whom the reconstitution of B cells is often accompanied by disease recurrence (58, 59). A 
subset of human T cells has been reported to express CD20 (60–62), and a small subset of 
human T and NK cells has been reported to be depleted following CD20 mAb therapy in 
rheumatoid arthritis patients due to low level CD20 expression (59, 61). However, 
measurable cell-surface CD20 expression is widely considered to be B cell restricted in 
humans (63) as it is in mice (4, 6). CD20 mAb treatment in patients with pemphigus 
decreases autoreactive CD4+ T cell frequencies, whereas overall T cell numbers are 
unaffected (64). Rituximab reduces both B and T cell numbers in cerebrospinal fluid of 
multiple sclerosis patients (65). Treg frequencies are reported to increase following 
rituximab treatment in patients with lupus or mixed cryoglobulinemia vasculitis (66–68). 
However, Treg and CD4+ T cell numbers decreased in parallel following CD20 mAb 
treatment in the current mouse study (Fig. 1D). The complexities of studying humans, 
particularly in those with disease undergoing therapy, in combination with the difficulties in 
assessing the extent of tissue B cell depletion, may thereby obfuscate studies of T cell 
alterations in patients acutely or chronically depleted of B cells. Likewise, B cell depletion 
in mice does not result in overt in vivo monocyte activation nor does it measurably influence 
serum cytokines that could in turn modify T cell function (16). That B cells are also required 
for T cell homeostasis in naive mice and for T cell activation during immune responses to 
pathogens provides a potential mechanism by which B cell depletion delays and reduces the 
severity of T cell–mediated autoimmune diseases (15, 17–19, 41, 69–71), even though 
serum Ig levels are not significantly affected by B cell depletion (2, 5).
The effects of CD20 mAb treatment on T cell numbers in the current study appears to be a 
direct consequence of B cell depletion and the disruption of lymphoid tissue architecture (8), 
consequently impairing cellular immunity. Thereby, the current results suggest a model in 
which the therapeutic benefits of CD20 mAb treatment in autoimmune patients are, at least 
in part, due to dysregulated T cell homeostasis and impaired T cell activation, with the 
potential cost of rendering some patients more susceptible to infections, particularly when 
given in combination with immunosuppressive drugs (58). Indeed, diminished T cell 
numbers and altered responses may explain rare infections in lymphoma patients receiving 
rituximab with microorganisms generally associated with T cell immunosuppression such as 
JC-papovavirus, CMV, or parvovirus B19 (72). Consequently, the impact of efficient B cell 
depletion on T cell responses observed in the current study urges caution in the broad and 
prolonged application of B cell depletion therapies in the clinic.
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B cell depletion alters T cell homeostasis. (A–D) Naive 2- or 4-mo-old mice were treated 
with control (closed circles) or CD20 (open circles) mAb, with viable single spleen and 
lymph node lymphocytes assessed 14 d later by immunofluorescence staining with flow 
cytometry analysis. Representative panels show B220+ versus LIVE/DEAD spleen B cell 
staining (left panels) and absolute B cell numbers (right panels) (A), CD4+ T cell numbers 
(B), CD8+ T cell numbers (C), and CD25 versus intracellular Foxp3 staining for CD4+ T 
cells (left panels) and Foxp3+CD25+CD4+ Treg numbers (right panels) (D) following B cell 
depletion. Pooled results from four independent experiments are indicated in graphs (n = 
10–21 mice/group with means indicated by horizontal bars). (E and F) CD4+ and CD8+ T 
cell migration is not profoundly impacted by B cell depletion. Dye-labeled B cell–depleted 
splenocytes were adoptively transferred into naive 2-mo-old mice given control or CD20 
mAb 7 d earlier. Absolute numbers of total endogenous and adoptively transferred dye+ 
CD4+ (E) and CD8+ (F) T cells within the blood, spleen, and lymph nodes were assessed 2 d 
later by immunofluorescence staining with flow cytometry analysis. Percentage differences 
in T cell numbers for CD20 mAb-treated relative to control mAb-treated mice are shown, in 
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which graphs show results from individual mice (n = 5 mice/group with means indicated by 
horizontal bars). (A–F) Mean cell frequencies (± SEM) within the indicated dot plot gates 
are shown. Significant differences between sample means are indicated: *p < 0.05, **p < 
0.01, ***p < 0.001. Ctrl, control.
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B cell depletion alters naive and memory T cell homeostasis. Naive 2- or 4-mo-old mice 
were treated with control (closed circles) or CD20 mAb (open circles). Viable, single spleen 
lymphocytes were isolated 14 d later (A–D) and depleted of B cells using CD19 mAb-
coated magnetic beads (C and D). The remaining non–B cells were cultured for 3.5 h with 
plate-bound CD3/CD28 mAbs before cell-surface CD4/CD8 labeling and intracellular 
cytokine staining with flow cytometry analysis. Representative panels show CD44 versus 
CD62L staining (left panels) and cell numbers (right panels) for CD4+ (A) and CD8+ (B) T 
cells. Representative panels show IFN-γ and TNF-α expression (left panels) and cell 
numbers (right panels) for CD4+ (C) and CD8+ (D) T cells. (A–D) Mean cell frequencies (± 
SEM) within the indicated dot plot gates are shown. Graphs show results from individual 
mice (n = 15–21 mice/group in three to four independent experiments) with means indicated 
by horizontal bars. Significant differences between sample means are indicated: **p < 0.01, 
***p < 0.001. Ctrl, control.
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Chronic B cell depletion alters T cell homeostasis and cytokine production. Naive 6-mo-old 
mice (n = 4–6 mice/group) were treated with control (closed circles) or CD20 mAb (open 
circles) monthly for 6 mo before spleen and lymph node (LN) lymphocyte isolation and 
analysis as in Figs. 1 and 2. (A) Chronic B cell depletion reduces CD4+ T cell and Treg cell 
numbers. Representative B220+ B cell depletion versus LIVE/DEAD cell staining, as well 
as B cell, CD4+, and CD8+ T cell, and Treg numbers are shown. (B) Chronic B cell 
depletion reduces CD4+ and CD8+ T cell activation. Representative panels show CD44 
versus CD62L staining (left panels) for CD4+ and CD8+ T cells and cell numbers (right 
panels). (C and D) Chronic B cell depletion impairs IFN-γ and TNF-α expression by CD4+ 
and CD8+ T cells. Representative panels show IFN-γ and TNF-α expression (left panels) 
and cell numbers (right panels) for CD4+ (C) and CD8+ (D) T cells. (A–D) Mean cell 
frequencies (± SEM) within the indicated dot plot gates are shown. Graphs show results 
from individual mice (n = 4–6 mice/group) with means indicated by horizontal bars. 
Significant differences between sample means are indicated: *p < 0.05, **p < 0.01, ***p < 
0.001. Ctrl, control.
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B cell depletion impairs T cell expansion, memory conversion, and virus clearance during 
LCMV infection. Naive 4-mo-old mice were given control (closed bars) or CD20 mAb 
(open bars) 7 d prior to treatment with PBS or infection with LCMV. Splenocytes harvested 
7 d later were assessed by immunofluorescence staining with flow cytometry analysis of 
viable, single lymphocytes. Representative panels show B220 versus CD4 staining (left 
panels) and B cell, CD4+, and CD8+ T cell numbers (right panels) (A) and CD25 versus 
intracellular Foxp3 staining for CD4+ T cells (left panels) and Treg numbers (right panels) 
(B). (C) B cell depletion reduces LCMV viral clearance. Spleens from control and CD20 
mAb-treated mice infected with LCMV were harvested 7 d postinfection, with viral RNA 
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levels quantified by RT-PCR. Bar graph values represent mean (± SEM) relative LCMV 
RNA expression levels (n = 4 mice/group in three independent experiments). (D–G) B cell 
depletion impairs LCMV-driven T cell activation and effector subset conversion. 
Representative panels show CD44 versus CD62L staining (left panels) for spleen CD4+ (D) 
and CD8+ T cells (F), with cell numbers for the spleen and lymph nodes shown (right 
panels). (E) Representative panels show PSGL1 versus Ly6C staining (left panels) for 
spleen and lymph node CD4+ cells, with activated CD4+ T cell conversion to effector (Eff; 
Ly6C+PSGL1+), prememory (Pre-M; Ly6C− PSGL1+), and T follicular helper (Tfh; Ly6C− 
PSGL1−) numbers shown (right panels). (G) Representative dot plots show CD127 versus 
KLRG1 staining (left panels) for spleen and lymph node CD8+ T cells, with KLRG1+ 
effector cell numbers shown (right panels). (A, B, D, and F) Graphs show mean (± SEM) 
numbers of the indicated cell types from mice treated with control or CD20 mAb (n = 21–26 
mice/group in four to five independent experiments). (E and G) Graphs show results from 
individual mice (n = 5 mice/group), with means indicated by horizontal bars. (A–G) Mean 
(± SEM) cell frequencies within the indicated dot plot gates are shown. Significant 
differences between sample means are indicated: *p < 0.05, **p < 0.01, ***p < 0.001. Ctrl, 
control.
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B cell depletion impairs T cell IFN-γ and TNF-α production during LCMV infection. Naive 
4-mo-old mice (n = 21–26 mice per group in four to five independent experiments) were 
given control (closed bars) or CD20 mAb (open bars) 7 d before infection with LCMV or 
treatment with PBS as in Fig. 4. Seven days postinfection, spleen lymphocytes were 
harvested, depleted of B cells with CD19 magnetic beads, and stimulated using plate-bound 
CD3/ CD28 mAbs as in Fig. 2. Intracellular cytokine production was assessed by 
immunofluorescence staining with flow cytometry analysis. Flow cytometry dot plots show 
representative CD4+ (A) or CD8+ (B) T cell cytokine staining (left panels), with mean (± 
SEM) cell frequencies shown for the indicated gates. Bar graphs represent mean (± SEM) 
numbers of the indicated cell types (right panels). Significant differences between sample 
means are indicated: *p < 0.05, **p < 0.01, ***p < 0.001. Ctrl, control.
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B cell depletion impairs Ag-specific T cell function. (A–D) B cell depletion impairs virus 
peptide-specific CD4+ and CD8+ T cell function. Naive 4-mo-old mice were given control 
(closed bars) or CD20 mAb (open bars) 7 d before infection with LCMVor treatment with 
PBS as in Figs. 4 and 5. Spleen and lymph node lymphocytes were harvested 7 d 
postinfection. (A) B cell depletion reduces LCMV GP66 tetramer+ CD4+ T cell and GP33 
tetramer+ CD8+ T cell numbers. Representative panels LCMV-specific tetramer staining 
(left panels) and cell numbers (right panels). (B) Representative panels show CD44 versus 
CD62L and PSGL1 versus Ly6C staining (top panels) for LCMV-specific GP66+ CD4+ T 
cells from the spleen and lymph nodes, with activated (CD44hiCD62Llo), effector 
(Ly6C+PSGL1+), prememory (Ly6C− PSGL1+), and T follicular helper (Tfh; Ly6C− 
PSGL1−) GP66+ CD4+ T cell numbers shown (bottom panels). B cell depletion reduces the 
frequencies and numbers of cytokine expressing LCMV-specific CD4+ (C) and CD8+ (D) T 
cells. Following B cell depletion using CD19 magnetic beads, T cells were stimulated with 
LCMV Armstrong GP61–80 or GP33–41 viral peptides for 5 h, with intracellular IFN-γ or 
TNF-α expression quantified by immunofluorescence staining. Flow cytometry dot plots 
show representative CD4 or CD8 expression versus cytokine staining. (E) B cell depletion 
impairs virus-specific CD8+ T cell effector development. Naive 4-mo-old mice were given 
control (closed bars) or CD20 mAb (open bars) 6 d before the adoptive transfer of naive 
TCR-transgenic CD8+ T cells that recognize GP33–41. Mice were infected with LCMV 1 d 
later and evaluated 7 d postinfection as in Figs. 4 and 5. Representative panels show CD44 
versus CD62L and CD127 versus KLRG1 staining (top panels) for transferred LCMV-
specific GP33+ CD8+ T cells from the spleen and lymph nodes, with numbers for total 
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(GP33+), activated (CD44hiCD62L+), effector (KLRG1+), and IFN-γ+ cells shown (bottom 
panels). (A, C, and D) Graphs show mean (± SEM) numbers of the indicated cell types from 
mice treated with control or CD20 mAb (n = 21–26 mice/group in four to five independent 
experiments). (B and E) Graphs show results from individual mice (n = 5 mice/group), with 
means indicated by horizontal bars. (B–E) Mean (± SEM) cell frequencies within the 
indicated dot plot gates are shown. Significant differences between sample means are 
indicated: *p < 0.05, **p < 0.01, ***p < 0.001. Ctrl, control.
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